Maladi ya kanser ya prostate eyebanaka na kotalela makambo mingi, na ndakisa ndenge kanser yango ezali, mbula ya moto ya maladi mpe nzoto na ye mobimba, mpe ndenge oyo baselile ya kanser ezali kobeba.
Na momeseno, kanser ya prostate ezalaka malamu, mingimingi soki emonani na ebandeli.
Motango ya bato oyo babikaka na mbula mitano mpo na kanser ya prostate oyo epalangani na esika moko te (kanser oyo epalangani na libándá ya prostate te) ezali pene na 100%.
Ezali na ntina kosolola na monganga mpo na koyeba ndenge maladi yango ekosuka, mpo ekoki kokesana na moto na moto.
Yang X, Wang R, Xu K, Yang F, Chen Y, Zuo Z, Song B: [Knockdown of myeloid cell leukemia 1 gene inhibits the proliferation and promotes apoptosis of prostate cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017, 33 (1): 62-66.
Kubota Y, Ito K, Imai K, Yamanaka H: Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002, 50 (4): 262-9.
Li K, Zhou H, Wang F, Zhao C, Fan C, Wang J: ZBTB38 suppresses prostate cancer cell proliferation and migration via directly promoting DKK1 expression. Cell Death Dis. 2021, 12 (11): 998.
Sun HF, Wang WD, Feng L: Effect of SPAG9 on migration, invasion and prognosis of prostate cancer. Int J Clin Exp Pathol. 2017, 10 (9): 9468-9474.
Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B: Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine (Baltimore). 2020, 99 (7): e18993.
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J, Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 2019, 121 (): 200-206.
Rucci N, Angelucci A: Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014, 2014 (): 167035.
['Koboya: makambo ya monganga']
['Site oyo ezali kaka mpo na koteya mpe koyebisa bato makambo ya monganga, kasi ezali te mpo na kopesa toli to toli ya monganga.']
['Makambo oyo ezali na site yango esengeli te kosalelama mpo na koyeba maladi to kosalisa yango, mpe baoyo balingi kozwa toli ya monganga basengeli kotuna yango epai ya monganga oyo ayebi mosala yango malamu.']
['Tosengi na yo oyeba ete réseau neuronal oyo epesaka biyano na mituna, ezalaka mpenza malamu te soki ezali na makambo ya mituya. Na ndakisa, motango ya bato oyo bazali na maladi moko boye.']
['Sololá ntango nyonso na monganga to na moto mosusu oyo ayebi kosalisa maladi na yo. Koboya toli ya monganga te to kozela te mpo otángi likambo moko na site oyo. Soki okanisi ete ozali na maladi oyo esengeli kosalisa yo nokinoki, bengá 911 to kende na lopitalo ya pene. Site oyo to ndenge oyo ozali kosalela yango ezali na boyokani te na monganga ná moto oyo azali kosalisa yo.']
["Kozanga ndingisa: droit d'auteur"]
['Mobeko ya Copyright ya Milenere ya 1998, 17 U.S.C. § 512 (DMCA) epesi nzela na bakomi ya mikanda oyo bakanisi ete biloko oyo ezali na Internet ezali kobebisa lotomo na bango na kolanda mibeko ya copyright ya Etats-Unis. ']
['Soki ondimi na motema malamu ete makambo to biloko oyo ezali na site Internet to na ba service na biso ezali kobuka mibeko na yo, yo (to moto oyo azali na mokumba ya kobatela yo) okoki kotindela biso mokanda mpo na kosɛnga ete tólongola makambo to biloko yango to tópekisa yo kokɔta na yango. ']
['Basengeli kotinda bansango na mokanda na nzela ya email (tala na "Kotindelana" mpo na adresse ya email). ']
['Mibeko ya DMCA esengi ete mokanda na yo ya kofunda mbeba ya copyright ezala na makambo oyo elandi: (1) kolimbola mosala oyo ezali na droit ya copyright oyo bazali kofunda ete ebebisami; (2) kolimbola makambo oyo bazali kofunda ete ebebisi mpe makambo oyo ekoki mpo na kosalisa biso na koyeba esika makambo yango ezali; (3) makambo ya kosolola na yo, ata mpe adrɛsi na yo, nimero ya telefone mpe adrɛsi ya e-mail; (4) mokanda oyo okomi ete ondimi na motema malamu ete makambo oyo ozali kofunda ete ebebisami epesami nzela te na nkolo ya droit ya copyright, to na agent na ye, to na mibeko nyonso; ']
['(5) mokanda oyo okomi, oyo okotya sinyatili na yango mpo na komonisa ete makambo oyo okomaki ezali solo mpe ete ozali na lotomo ya kolandela lotomo ya babimisi oyo bazali koloba ete ebebisami; ']
['mpe (6) sinyatili ya moto oyo azali na lotomo ya kosala yango to ya moto oyo azali na lotomo ya kosala na nkombo na ye. ']
['Soki otye makambo nyonso te oyo ezali awa na likolo, yango ekoki kosala ete likambo na yo eumela.']
['Ndenge ya kosolola']
['Tosengi otindela biso email na motuna to likanisi nyonso.']
What is prognosis of prostate cancer?
The prognosis of prostate cancer depends on several factors, including the stage of the cancer, the patient's age and overall health, and the aggressiveness of the cancer cells.
In general, prostate cancer has a good prognosis, especially when caught early.
The 5-year survival rate for localized prostate cancer (cancer that has not spread beyond the prostate) is nearly 100%. However, the prognosis worsens as the cancer progresses and spreads to other parts of the body.
It is important to discuss the specific prognosis with a healthcare professional, as it can vary greatly from person to person.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na ntina na']
['BioMedLib esalelaka ba ordinateur oyo esalemi na masini (machine-learning algorithms) mpo na kobimisa mituna mpe biyano.']
['Tobandi na mikanda ya minganga 35 millions ya PubMed/Medline. Lisusu, ba pages ya RefinedWeb.']
